This article discusses the use of human induced pluripotent stem cell-derived cardiomyocytes as a rapid screening tool to assess the heart-related risks of new nicotine products like heated tobacco and vaping devices.
It highlights the importance of understanding these risks to inform public health policies and protect consumers from potential cardiovascular harm associated with these emerging products.